Aligos Therapeutics, Inc. - Common stock —— 季度现金流量表 (NASDAQ:ALGS)

Financials

总资产 70.09 M150.7 M134.71 M109.76 M88.53 M64.56 M 负债总额 99.07 M34.25 M32.84 M37.93 M34.99 M32.77 M 权益总额 -28.97 M116.44 M101.87 M71.83 M53.55 M31.79 M 负债及股东权益总额 70.09 M150.7 M134.71 M109.76 M88.53 M64.56 M 总债务 —————— 净债务 ——————

新闻

H.C. Wainwright维持Aligos Therapeutics股票买入评级，看好pevifoscorvir研发进展

Aligos Therapeutics stock maintains Buy rating at H.C. Wainwright on pevifoscorvir progress

Aligos Therapeutics股价因乙肝二期研究进展而上涨

Aligos Therapeutics stock rises on Phase 2 HBV study progress

Aligos公布乙肝药物二期研究进展

Aligos reports progress on Phase 2 hepatitis B drug study

Aligos Therapeutics任命James Hassard为首席商务官

Aligos therapeutics appoints James Hassard as chief commercial officer

UBS以肝脏疾病管线为由给Aligos Therapeutics股票首次评级为"买入"

Aligos Therapeutics stock initiated with Buy rating at UBS on liver disease pipeline

Aligos报告THR-β激动剂协同减重效果

Aligos reports synergistic weight loss effect with THR-β agonist